A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2023-03-24
Adverse events
Grade 2 Pruritus — outcome: RECOVERED/RESOLVED; onset 2023-06-18 (study day 76); relationship: not assessed
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-06-27 (study day 85); relationship: not assessed
Grade 4 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-08-09 (study day 128); relationship: not assessed; serious criteria: life-threatening
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-08-19 (study day 138); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-10-01 (study day 181); relationship: not assessed
Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-11-07 (study day 218); relationship: not assessed; serious criteria: hospitalization
Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-12-02 (study day 243); relationship: not assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-01-25 (study day 297); relationship: N
Data queries
No data queries.